RMTI Rockwell Medical, Inc. - Common Stock
$7,58
Harga · Agu 19, 2026
Fundamental per Agu 13, 2026
Rentang 52M
$1–$8
95% of range
Peringkat Analis
BUY
8 analysts
Target Harga
$30
+296% upside
P/E (TTM)
-5.1
ROE
-15.8%
Margin Laba Bersih
-7.7%
Tentang Rockwell Medical, Inc. - Common Stock Tinjauan perusahaan dari Wikipedia
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
Baca selengkapnya
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
The company's primary customers are dialysis providers.
Products
Triferic
Triferic was approved by the Food and Drug Administration (FDA) in January 2015. Triferic is the only FDA-approved therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients with chronic kidney disease. Triferic replaces the iron lost during hemodialysis treatments. Triferic delivers iron directly to transferrin which transports it to the bone marrow to make hemoglobin. Rockwell is actively marketing and commercializing Triferic in the U.S. hemodialysis market. In February 2014, the Company completed its long-term safety study for Triferic.
Rockwell Medical began commercializing Triferic (dialysate) and Triferic AVNU (intravenous) in the United States in the second half of 2019 and in early 2021, respectively. Triferic was launched into a very competitive marketplace with well-entrenched products and a lack of consensus regarding unmet medical needs for dialysis patients with anemia. Due to its limited market adoption, unfavorable reimbursement, and absence of interest from other companies to license or acquire Triferic despite Rockwell's significant effort to partner the program, Rockwell Medical discontinued its New Drug Applications (“NDAs”) for Triferic and Triferic AVNU in the United States in the fourth quarter of 2022.
Calcitriol
Calcitriol (active vitamin D) generic is FDA approved for treating secondary hyperparathyroidism or hypocalcemia in hemodialysis patients.
Hemodialysis Concentrates
Rockwell is a manufacturer of hemodialysis concentrates/dialysates for dialysis providers and distributors in the U.S. and globally. Hemodialysis concentrates remove toxins and replace critical nutrients in the dialysis patient's bloodstream during hemodialysis. Rockwell has three U.S. manufacturing and distribution facilities.
Iron (III) pyrophosphate
One of the main treatments that the company develops is iron (III) pyrophosphate, for iron supplementation, a key element in the formation of new red blood cells. It was licensed in 2011 for the delivery of iron supplementation for patients who suffer from anemic dialysis since the process accounts for treatment in around 90% of anemia patients.
International Partnerships
While Rockwell has discontinued commercialization of Triferic in the United States, the company has established international partnerships with companies seeking to develop and commercialize Triferic outside the United States and is working closely with these international partners to develop and commercialize Triferic in their respective regions.
South Korea for example; Triferic and Triferic AVNU have been approved in South Korea, and our partner, Jeil Pharmaceutical, launched Triferic in South Korea during the third quarter of 2022.
Also, in April 2023, Drogsan submitted a Marketing Authorization application and GMP application for Triferic AVNU to the Turkish Medicines and Medical Devices Agency ("TMMDA"), for which Drogsan received priority status and high priority status, respectively. Taking into consideration that Drogsan was granted an accelerated review for Triferic AVNU with the Turkish regulatory authority, Rockwell anticipates approval for Triferic AVNU in Turkey in 2024. Drogsan is responsible for all regulatory approval and commercialization activities.
Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗
RMTI Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
Harga
$7.58
Kapitalisasi Pasar
$30M
P/E (TTM)
-5.1
EPS (TTM)
$-0.15
Pendapatan (TTM)
$69M
Imbal Hasil Dividen
—
ROE
-15.8%
D/E Utang/Ekuitas
0.2
Rentang 52M
$1 – $8
RMTI Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
Configure
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Pendapatan & Laba Bersih
$69M
2016-12-31
→
2025-12-31
EPS
$-0.15
2016-12-31
→
2025-12-31
Arus Kas Bebas
$-1M
2024-12-31
→
2025-12-31
Margin
-7.7%
2016-12-31
→
2025-12-31
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
Metrik
Tren 5 Tahun
RMTI
Median Rekan
P/E (TTM)
-5.1
15.4
P/S (TTM)
0.4
2.8
P/B
0.8
1.6
EV / EBITDA
-11.2
—
Price / FCF (Harga / FCF)
-24.9
—
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
Metrik
Tren 5 Tahun
RMTI
Median Rekan
Gross Margin (Margin Kotor)
16.9%
31.6%
Operating Margin (Margin Operasi)
-6.8%
—
Net Profit Margin (Margin Laba Bersih)
-7.7%
-49.3%
ROA
-9.1%
-54.9%
ROE
-15.8%
-98.0%
ROIC
-10.2%
—
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
Metrik
Tren 5 Tahun
RMTI
Median Rekan
Debt / Equity (Utang / Ekuitas)
0.2
0.0
Current Ratio (Rasio Lancar)
4.0
4.7
Quick Ratio (Rasio Cepat)
2.0
—
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
Metrik
Tren 5 Tahun
RMTI
Median Rekan
Revenue YoY (Pendapatan YoY)
-31.8%
—
Revenue CAGR 3Y (CAGR Pendapatan 3T)
-1.7%
—
Revenue CAGR 5Y (CAGR Pendapatan 5T)
2.2%
—
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
Metrik
Tren 5 Tahun
RMTI
Median Rekan
RMTI Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
BELI
8 analis
- Beli Kuat 2 25,0%
- Beli 5 62,5%
- Tahan 1 12,5%
- Jual 0 0,0%
- Jual Kuat 0 0,0%
Target Harga 12 Bulan
2 analis · 2026-08-15
Median
$30.00
← Di bawah semua target
$7.58
Rendah
$20.00
Tinggi
$40.00
Target median
$30.00
+295,8%
Target rata-rata
$30.00
+295,8%
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
Kejutan Rata-rata
-0.09%
| Periode | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|
| 30 Juni 2026 | $-0.34 | $-0.24 | -0.10% |
| 31 Maret 2026 | $-0.40 | $-0.26 | -0.14% |
| 31 Des. 2025 | $-0.10 | $0.20 | -0.30% |
| 30 Sep. 2025 | $-0.50 | $-0.46 | -0.04% |
| 30 Juni 2025 | $-0.50 | $-0.51 | 0.01% |
| 31 Maret 2025 | $-0.04 | $-0.05 | 0.01% |
| 31 Des. 2024 | $-0.02 | $0.02 | -0.04% |
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| RMTI | $33M | -5.5 | -31.8% | -7.7% | -15.8% | 16.9% |
| UTMD | $178M | 16.1 | -5.8% | 29.3% | 9.5% | 57.1% |
| NSPR | $77M | -2.3 | 28.1% | -543.3% | -129.3% | 29.5% |
| TELA | $53M | -1.4 | 15.8% | -48.4% | -501.1% | 67.7% |
| ADVB | $15M | -4.4 | — | — | -159.1% | — |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi 17
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $69M | $101M | $84M | $73M | $62M | $62M | $61M | $63M | $57M | $53M | $55M | $54M | |
| Cost of Revenue | $58M | $84M | $75M | $69M | $64M | $59M | $58M | $65M | $54M | $47M | $46M | $46M | |
| Gross Profit | $12M | $17M | $9M | $4M | $-2M | $3M | $3M | $-2M | $4M | $7M | $9M | $9M | |
| R&D Expense | $0 | $19.0K | $1M | · | · | · | · | $6M | $6M | $6M | $5M | $8M | |
| SG&A Expense | $14M | $14M | $12M | $16M | $15M | $16M | $21M | $22M | $23M | $21M | $19M | $18M | |
| Operating Income | $-5M | $608.0K | $-7M | $-17M | $-30M | $-28M | $-35M | $-32M | $-26M | $-20M | $-15M | $-18M | |
| Interest Expense | · | · | $2M | $2M | $2M | $2M | $25.0K | · | · | · | · | · | |
| Interest Income | · | · | $211.0K | $33.0K | $22.0K | $238.0K | $392.0K | · | · | · | · | · | |
| Other Non-op | $-623.0K | $-1M | $-2M | $-2M | $-2M | $-2M | $397.0K | $313.3K | $1.6K | · | · | · | |
| Pretax Income | $-5M | $-480.0K | $-8M | · | · | · | · | · | $-26M | $-19M | $-14M | $-21M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $404.5K | $0 | $0 | |
| Net Income | $-5M | $-480.0K | $-8M | $-19M | $-33M | $-31M | $-34M | $-32M | $-26M | $-20M | $-14M | $-21M | |
| EPS (Basic) | $-0.15 | $-0.03 | $-0.37 | $-1.31 | $-3.83 | $-0.41 | · | · | $-0.51 | $-0.39 | $-0.29 | $-0.52 | |
| EPS (Diluted) | $-0.15 | $-0.03 | $-0.37 | $-1.31 | $-3.83 | $-0.41 | · | · | $-0.51 | $-0.39 | $-0.29 | $-0.52 | |
| Shares (Basic) | 35,974,231 | 31,058,539 | 23,322,915 | 14,304,512 | 8,526,186 | 75,621,674 | · | · | 51,067,412 | 50,676,180 | 50,068,129 | 41,404,999 | |
| Shares (Diluted) | 35,974,231 | 31,058,539 | 23,322,915 | 14,304,512 | 8,526,186 | 75,621,674 | · | · | 51,067,412 | 50,676,180 | 50,068,129 | 41,404,999 | |
| EBITDA | $-2M | $3M | $-5M | $-16M | $-30M | $-28M | $-34M | $-32M | $-25M | $-19M | $-14M | $-17M |
Neraca 29
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11M | $16M | $9M | $10M | $13M | $49M | $12M | $23M | $8M | $17M | $31M | $66M | |
| Short-term Investments | · | · | · | · | · | · | · | $11M | $25M | $41M | $39M | $20M | |
| Receivables | $8M | $8M | $11M | $6M | $6M | $4M | $4M | $7M | $6M | $6M | $5M | $4M | |
| Inventory | $3M | $6M | $6M | $6M | $4M | $4M | $4M | $4M | $8M | $12M | $8M | $4M | |
| Prepaid Expense | $2M | $1M | $1M | $2M | $3M | $3M | $3M | $2M | $2M | · | · | · | |
| Other Current Assets | · | · | · | · | · | · | · | · | $2M | $2M | $1M | $587.2K | |
| Current Assets | $38M | $37M | $29M | $35M | $35M | $69M | $37M | $47M | $49M | $79M | $85M | $95M | |
| PP&E (Net) | $5M | $6M | $6M | $2M | $2M | $3M | $2M | $3M | $3M | $1M | $2M | $1M | |
| PP&E (Gross) | $15M | $16M | $15M | $10M | $10M | $9M | $8M | $9M | $12M | $11M | $11M | $10M | |
| Accum. Depreciation | $11M | $10M | $9M | $8M | $7M | $7M | $6M | $6M | $9M | $10M | $9M | $9M | |
| Goodwill | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $920.7K | $920.7K | $920.7K | $920.7K | $920.7K | |
| Intangibles | $10M | $10M | $11M | $0 | · | · | · | · | $4.0K | $4.4K | $165.7K | $332.7K | |
| Other Non-current Assets | $556.0K | $528.0K | $527.0K | $523.0K | $619.0K | $629.0K | $435.0K | $536.5K | $494.8K | $501.2K | $462.8K | $542.2K | |
| Total Assets | $57M | $59M | $52M | $47M | $49M | $78M | $44M | $53M | $59M | $83M | $88M | $98M | |
| Accounts Payable | $2M | $3M | $5M | $4M | $4M | $4M | $3M | $4M | $4M | $6M | $4M | $5M | |
| Accrued Liabilities | $4M | $6M | $7M | $8M | $5M | $5M | $5M | $5M | $5M | $4M | $4M | $4M | |
| Current Liabilities | $10M | $14M | $17M | $18M | $21M | $13M | $12M | $13M | $9M | $10M | $8M | $10M | |
| Capital Leases | $1M | $2M | $1M | $3M | · | $2M | $2M | · | · | · | · | · | |
| Other Non-current Liabilities | · | $0 | $14.0K | $14.0K | $14.0K | $0 | · | · | · | · | · | · | |
| Total Liabilities | $20M | $27M | $31M | $33M | $46M | $44M | $24M | $25M | $26M | · | · | · | |
| Long-term Debt | $9M | · | $8M | $9M | $21M | $21M | · | · | · | · | · | · | |
| Total Debt | $9M | $8M | $8M | $9M | $21M | $21M | · | · | · | · | · | · | |
| Common Stock | · | · | · | · | · | · | · | · | · | $268M | $258M | $249M | |
| Paid-in Capital | $440M | $430M | $418M | $403M | $373M | $372M | $327M | $300M | · | · | · | · | |
| Retained Earnings | $-403M | $-398M | $-397M | $-389M | $-370M | $-337M | $-307M | $-272M | $-240M | $-214M | $-195M | $-180M | |
| AOCI | $131.0K | $54.0K | $-1.0K | $163.0K | $52.0K | $57.0K | $52.0K | $63.1K | $-35.4K | $-902.5K | $-915.5K | $-197.7K | |
| Stockholders' Equity | $37M | $33M | $21M | $14M | $3M | $34M | $20M | $27M | $33M | $53M | $62M | $69M | |
| Liabilities + Equity | $57M | $59M | $52M | $47M | $49M | $78M | $44M | $53M | $59M | $83M | $88M | $98M | |
| Shares Outstanding | 3,940,530 | 3,405,692 | 29,130,607 | 12,163,673 | 8,544,225 | 8,506,651 | 65,378,890 | 57,034,154 | 51,768,424 | 51,527,711 | 51,501,877 | 50,284,007 |
Arus Kas 16
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $2M | $2M | $1M | $576.0K | $668.0K | $834.0K | $788.0K | $650.1K | $514.4K | $762.4K | $822.3K | $996.3K | |
| Stock-based Comp | $2M | $1M | $932.0K | $315.0K | $943.0K | $475.0K | $5M | $4M | $7M | $10M | $9M | $10M | |
| Amort. of Intangibles | · | · | $300.0K | · | · | · | · | · | · | · | · | · | |
| Restructuring | $1M | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | $-966.0K | $-317.0K | $-11M | $-2M | $-7M | $-3M | $-887.5K | $3M | $-6M | $-8M | $-20M | $27M | |
| Operating Cash Flow | $-659.0K | $4M | $-9M | $-17M | $-34M | $-30M | $-27M | $-20M | $-21M | $-12M | $-13M | $4M | |
| CapEx | $542.0K | $1M | $284.0K | · | · | · | · | · | · | · | · | · | |
| Investing Cash Flow | $-9M | $-5M | $-3M | $-2M | $311.0K | $3M | $-5M | $13M | $15M | $-2M | $-21M | $-9M | |
| Debt Issued | · | · | · | · | $0 | $22M | $0 | · | · | · | · | · | |
| Net Debt Issued | · | · | · | · | $0 | $22M | · | · | · | · | · | · | |
| Stock Issued | $8M | $10M | $15M | $15M | · | · | $5M | $22M | $123.6K | · | · | · | |
| Net Stock Activity | $8M | $10M | $15M | · | · | · | · | $22M | · | · | · | · | |
| Financing Cash Flow | $4M | $7M | $11M | $16M | $-2M | $63M | $21M | $22M | $-2M | $80.2K | $-132.7K | $58M | |
| Net Change in Cash | $-5M | $7M | $-1M | $-3M | $-35M | $37M | $-11M | $14M | $-9M | $-14M | $-35M | $54M | |
| Taxes Paid | $0 | · | · | · | · | · | · | · | · | $404.5K | · | · | |
| Free Cash Flow | $-1M | $3M | · | · | · | · | · | · | · | · | · | · |
Profitabilitas 8
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 16.9% | 17.2% | 10.4% | 5.6% | -3.9% | 4.4% | 4.6% | -2.5% | 6.5% | 12.7% | 16.2% | 15.8% | |
| Operating Margin | -6.8% | 0.60% | -8.0% | -23.1% | -49.0% | -45.7% | -56.3% | -51.2% | -45.2% | -37.9% | -27.3% | -32.4% | |
| Net Margin | -7.7% | -0.47% | -10.1% | -25.7% | -52.8% | -49.7% | -55.7% | -50.7% | -45.2% | -37.2% | -26.1% | -39.4% | |
| Pretax Margin | -7.7% | -0.47% | · | · | · | · | · | · | -45.2% | -36.4% | -26.1% | -39.4% | |
| EBITDA Margin | -3.6% | 2.8% | -6.2% | -22.3% | -47.9% | -44.4% | -55.0% | -50.1% | -44.3% | -36.5% | -25.8% | -30.6% | |
| ROA | -9.1% | -0.86% | -17.1% | -39.2% | -51.7% | -50.6% | -70.5% | -57.7% | -36.5% | -23.2% | -15.5% | -31.8% | |
| ROE | -15.8% | -1.6% | -39.4% | -123.5% | -479.5% | -81.0% | -155.1% | -160.8% | -60.4% | -34.4% | -22.0% | -61.6% | |
| ROIC | -10.2% | 1.5% | · | · | · | · | · | · | -78.8% | -39.0% | -24.2% | -25.6% |
Likuiditas & Solvabilitas 5
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.0 | 2.6 | 1.7 | 2.0 | 1.7 | 5.4 | 3.0 | 3.5 | 5.3 | 7.7 | 10.5 | 9.7 | |
| Quick Ratio | 2.0 | 1.7 | 1.2 | 0.9 | 0.9 | 4.1 | 1.3 | 3.1 | 4.3 | 6.3 | 9.4 | 9.2 | |
| Debt / Equity | 0.2 | 0.3 | 0.4 | 0.7 | 8.1 | 0.6 | · | · | · | · | · | · | |
| LT Debt / Equity | 0.2 | 0.3 | 0.4 | 0.5 | 5.2 | 0.6 | · | · | · | · | · | · | |
| Interest Coverage | · | · | -2.9 | -8.7 | -12.9 | -15.1 | · | · | · | · | · | · |
Efisiensi 3
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.2 | 1.8 | 1.7 | 1.5 | 1.0 | 1.0 | 1.3 | 1.1 | 0.8 | 0.6 | 0.6 | 0.8 | |
| Inventory Turnover | 12.5 | 14.4 | 12.8 | 13.9 | 16.1 | 15.7 | 15.2 | 11.1 | 5.4 | 4.7 | 7.9 | 13.6 | |
| Receivables Turnover | 8.4 | 10.6 | 9.7 | 12.0 | 12.3 | 14.9 | 11.0 | 9.5 | 9.0 | 9.3 | 11.6 | 12.0 |
Tingkat Pertumbuhan 3
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -31.8% | 21.4% | 14.8% | 17.6% | -0.43% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -1.7% | 17.9% | 10.4% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 2.2% | · | · | · | · | · | · | · | · | · | · | · |
Valuasi (TTM) 14
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $69M | $101M | $84M | $73M | $62M | $62M | $61M | $63M | $57M | $53M | $55M | $54M | |
| Net Income TTM | $-5M | $-480.0K | $-8M | $-19M | $-33M | $-31M | $-34M | $-32M | $-26M | $-20M | $-14M | $-21M | |
| Market Cap | $33M | $69M | $55M | $12M | $424M | $1.04B | $1.75B | $1.42B | $3.31B | $3.71B | $5.80B | $5.69B | |
| Enterprise Value | $31M | $62M | $54M | $11M | $431M | $1.01B | · | · | · | · | · | · | |
| P/E | -5.5 | -68.0 | -5.1 | -0.8 | -1.2 | -27.1 | -58.3 | -54.0 | -125.5 | -184.7 | -388.4 | -217.5 | |
| P/S | 0.5 | 0.7 | 0.7 | 0.2 | 6.8 | 16.7 | 28.6 | 22.4 | 57.8 | 69.7 | 104.8 | 104.9 | |
| P/B | 0.9 | 2.1 | 2.6 | 0.9 | 167.2 | 30.4 | 86.4 | 52.0 | 100.7 | 70.1 | 93.1 | 82.8 | |
| P / Tangible Book | 1.2 | 3.2 | 5.7 | 0.9 | 262.6 | 31.3 | · | · | · | · | · | · | |
| P / Cash Flow | -49.6 | 16.5 | -5.8 | -0.7 | -12.6 | -35.1 | -64.3 | -69.4 | -157.0 | -298.1 | -357.2 | 1335.5 | |
| P / FCF | -27.2 | 21.8 | · | · | · | · | · | · | · | · | · | · | |
| EV / EBITDA | -12.3 | 22.3 | -10.4 | -0.7 | -14.5 | -36.7 | · | · | · | · | · | · | |
| EV / FCF | -25.7 | 19.5 | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 0.4 | 0.6 | 0.7 | 0.2 | 7.0 | 16.3 | · | · | · | · | · | · | |
| Earnings Yield | -18.1% | -1.5% | -19.6% | -129.7% | -84.9% | -3.7% | -1.7% | -1.8% | -0.80% | -0.54% | -0.26% | -0.46% |
Laporan Laba Rugi 14
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $18M | $17M | $18M | $16M | $16M | $19M | $25M | $28M | $26M | $23M | $22M | $24M | $18M | $20M | $19M | $19M | |
| Cost of Revenue | $15M | $14M | $14M | $14M | $14M | $16M | $21M | $22M | $21M | $20M | $19M | $22M | $17M | $17M | $17M | $18M | |
| Gross Profit | $3M | $3M | $4M | $2M | $3M | $3M | $4M | $6M | $5M | $3M | $3M | $2M | $1M | $3M | $2M | $777.0K | |
| R&D Expense | $40.0K | · | $0 | $0 | $0 | $0 | $1.0K | $0 | $0 | $18.0K | $168.0K | $494.0K | $167.0K | $278.0K | · | $469.0K | |
| SG&A Expense | $4M | $4M | $4M | $3M | $3M | $4M | $3M | $4M | $3M | $4M | $3M | $3M | $3M | $3M | $4M | $3M | |
| Operating Income | $-1M | $-1M | $-398.0K | $-2M | $-1M | $-1M | $-519.0K | $2M | $515.0K | $-1M | $-547.0K | $-2M | $-3M | $-1M | $-2M | $-4M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $431.0K | · | $411.0K | $395.0K | $387.0K | $435.0K | $476.0K | |
| Other Non-op | $-111.0K | $-125.0K | $-156.0K | $-169.0K | $-143.0K | $-155.0K | $-237.0K | $-272.0K | $-172.0K | $-407.0K | $-965.0K | $-135.0K | $-346.0K | $-323.0K | $-396.0K | $-482.0K | |
| Net Income | $-1M | $-2M | $-554.0K | $-2M | $-1M | $-2M | $-756.0K | $2M | $343.0K | $-2M | $-2M | $-2M | $-3M | $-2M | $-2M | $-4M | |
| EPS (Basic) | $-0.34 | $-0.04 | $-0.01 | $-0.05 | $-0.48 | $-0.04 | $-0.03 | $0.05 | $0.01 | $-0.06 | $-0.02 | $-0.07 | $-0.18 | $-0.10 | $0.19 | $-0.23 | |
| EPS (Diluted) | $-0.70 | $-0.04 | $-0.01 | $-0.05 | $-0.05 | $-0.04 | $-0.02 | $0.04 | $0.01 | $-0.06 | $-0.02 | $-0.07 | $-0.18 | $-0.10 | $0.19 | $-0.23 | |
| Shares (Basic) | 3,958,568 | 39,418,302 | -68,469,655 | 36,024,940 | 3,431,130 | 34,107,640 | -60,272,092 | 31,551,805 | 30,451,622 | 29,327,204 | -41,054,753 | 27,521,088 | 18,496,640 | 18,359,940 | -24,295,154 | 18,463,673 | |
| Shares (Diluted) | 3,958,568 | 39,418,302 | -68,469,655 | 36,024,940 | 3,431,130 | 34,107,640 | -62,722,609 | 32,420,168 | 32,033,776 | 29,327,204 | -41,054,753 | 27,521,088 | 18,496,640 | 18,359,940 | -24,295,154 | 18,463,673 | |
| EBITDA | $-1M | $-969.0K | · | $-2M | $-1M | $-821.0K | · | $2M | $515.0K | $-779.0K | · | $-2M | $-3M | $-1M | · | $-4M |
Neraca 26
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11M | $10M | $11M | $14M | $12M | $11M | $16M | $12M | $12M | $7M | $9M | $8M | $9M | $11M | $10M | $13M | |
| Receivables | $8M | $9M | $8M | $8M | $8M | $10M | $8M | $9M | $11M | $11M | $11M | $9M | $5M | $6M | $6M | $7M | |
| Inventory | $3M | $3M | $3M | $4M | $4M | $5M | $6M | $6M | $6M | $6M | $6M | $5M | $6M | $6M | $6M | $5M | |
| Prepaid Expense | $441.0K | $1M | $2M | $2M | $943.0K | $988.0K | $1M | $1M | $1M | $910.0K | $1M | $2M | $1M | $1M | $2M | $2M | |
| Current Assets | $36M | $37M | $38M | $38M | $32M | $33M | $37M | $34M | $30M | $27M | $29M | $28M | $28M | $30M | $35M | $42M | |
| PP&E (Net) | $5M | $4M | $5M | $5M | $5M | $5M | $6M | $6M | $6M | $6M | $6M | $7M | $2M | $2M | $2M | $2M | |
| PP&E (Gross) | $14M | $14M | $15M | $16M | $16M | $16M | $16M | $16M | $16M | $15M | $15M | $15M | $10M | $10M | $10M | $10M | |
| Accum. Depreciation | $9M | $10M | $11M | $12M | $11M | $11M | $10M | $10M | $10M | $9M | $9M | $8M | $8M | $8M | $8M | $7M | |
| Goodwill | $920.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | |
| Intangibles | $9M | $10M | $10M | $10M | $10M | $10M | $10M | $10M | $10M | $11M | $11M | $11M | · | · | $0 | · | |
| Other Non-current Assets | $556.0K | $556.0K | $556.0K | $561.0K | $561.0K | $521.0K | $528.0K | $548.0K | $548.0K | $527.0K | $527.0K | $527.0K | $527.0K | $522.0K | $523.0K | $522.0K | |
| Total Assets | $57M | $57M | $57M | $57M | $53M | $54M | $59M | $57M | $53M | $51M | $52M | $53M | $38M | $40M | $47M | $54M | |
| Accounts Payable | $3M | $3M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $5M | $5M | $4M | $6M | $5M | $4M | $3M | |
| Accrued Liabilities | $4M | $3M | $4M | $4M | $4M | $5M | $6M | $6M | $6M | $5M | $7M | $7M | $4M | $4M | $8M | $6M | |
| Current Liabilities | $11M | $10M | $10M | $10M | $11M | $11M | $14M | $14M | $15M | $15M | $17M | $21M | $17M | $15M | $18M | $19M | |
| Capital Leases | $3M | $3M | $1M | $2M | $2M | $1M | $2M | $2M | $2M | $3M | $1M | $2M | $2M | $2M | $3M | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | |
| Total Liabilities | $21M | $22M | $20M | $20M | $22M | $22M | $27M | $28M | $30M | $30M | $31M | $31M | $29M | $28M | $33M | $38M | |
| Long-term Debt | $9M | $9M | · | · | · | · | · | · | · | · | · | $9M | $9M | $9M | $9M | $14M | |
| Total Debt | $9M | $9M | · | $9M | $9M | $9M | · | $8M | $8M | $8M | · | $9M | $9M | $9M | · | $14M | |
| Paid-in Capital | $441M | $440M | $440M | $439M | $431M | $431M | $430M | $426M | $422M | $420M | $418M | $417M | $403M | $403M | $403M | $402M | |
| Retained Earnings | $-406M | $-405M | $-403M | $-402M | $-401M | $-399M | $-398M | $-397M | $-399M | $-399M | $-397M | $-396M | $-394M | $-391M | $-389M | $-386M | |
| AOCI | $130.0K | $133.0K | $131.0K | $73.0K | $57.0K | $60.0K | $54.0K | $8.0K | $-5.0K | $24.0K | $-1.0K | $68.0K | $137.0K | $156.0K | $163.0K | $54.0K | |
| Stockholders' Equity | $35M | $36M | $37M | $37M | $30M | $32M | $33M | $29M | $23M | $21M | $21M | $22M | $10M | $13M | $14M | $16M | |
| Liabilities + Equity | $57M | $57M | $57M | $57M | $53M | $54M | $59M | $57M | $53M | $51M | $52M | $53M | $38M | $40M | $47M | $54M | |
| Shares Outstanding | 3,972,029 | 39,470,299 | 39,405,302 | 39,405,301 | 34,430,352 | 34,257,903 | 34,056,920 | 32,318,806 | 31,030,218 | 29,556,474 | 29,130,607 | 28,489,663 | 16,795,673 | 12,552,673 | 12,163,673 | 11,152,673 |
Arus Kas 13
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $492.0K | $511.0K | $546.0K | $544.0K | $563.0K | $539.0K | $543.0K | $543.0K | $549.0K | $545.0K | $550.0K | $564.0K | $170.0K | $160.0K | $154.0K | $143.0K | |
| Stock-based Comp | $403.0K | $479.0K | $457.0K | $532.0K | $382.0K | $445.0K | $382.0K | $321.0K | $338.0K | $251.0K | $218.0K | $212.0K | $309.0K | $193.0K | $220.0K | $177.0K | |
| Amort. of Intangibles | · | · | · | · | · | · | · | · | · | · | · | $100.0K | · | · | · | · | |
| Restructuring | · | · | $200.0K | $500.0K | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $448.0K | · | · | · | $-3M | · | · | · | $-1M | · | · | · | $-6M | · | · | |
| Operating Cash Flow | $2M | $-167.0K | $2M | $-1M | $2M | $-3M | $865.0K | $4M | $1M | $-2M | $-43.0K | $-4M | $-2M | $-4M | $-112.0K | $-1M | |
| CapEx | $617.0K | $425.0K | $86.0K | $229.0K | $164.0K | $63.0K | $395.0K | $191.0K | $286.0K | $139.0K | $43.0K | · | · | · | · | · | |
| Investing Cash Flow | $-487.0K | $-122.0K | $-4M | $-4M | $-103.0K | $-1.0K | $-332.0K | $-6M | $2M | $-139.0K | $2M | $-10M | $-64.0K | $5M | $3M | $-15M | |
| Stock Issued | · | · | $0 | $8M | $0 | $0 | $4M | $4M | $2M | $560.0K | $1M | $14M | $0 | $0 | $0 | $0 | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $560.0K | · | · | · | · | · | · | |
| Financing Cash Flow | $-683.0K | $-813.0K | $-1M | $7M | $-650.0K | $-783.0K | $3M | $2M | $2M | $178.0K | $-742.0K | $13M | $-130.0K | $-631.0K | $-6M | $-2M | |
| Net Change in Cash | $910.0K | $-1M | $-3M | $1M | $1M | $-4M | $3M | $475.0K | $5M | $-2M | $1M | $-1M | $-2M | $792.0K | $-3M | $-18M | |
| Free Cash Flow | · | $-592.0K | · | · | · | $-4M | · | · | · | · | · | · | · | · | · | · |
Profitabilitas 6
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 18.2% | 16.7% | · | 14.3% | 15.6% | 16.1% | · | 22.0% | 17.6% | 13.5% | · | 9.3% | 5.7% | 13.2% | · | 4.2% | |
| Operating Margin | -6.0% | -8.5% | · | -10.0% | -8.4% | -7.2% | · | 6.8% | 2.0% | -5.8% | · | -7.3% | -16.4% | -7.3% | · | -19.8% | |
| Net Margin | -6.6% | -9.3% | · | -11.0% | -9.3% | -8.0% | · | 5.9% | 1.3% | -7.6% | · | -7.9% | -18.3% | -8.9% | · | -22.4% | |
| EBITDA Margin | -6.0% | -5.6% | · | -10.0% | -8.4% | -4.3% | · | 6.8% | 2.0% | -3.4% | · | -7.3% | -16.4% | -6.4% | · | -19.8% | |
| ROA | -2.1% | -2.9% | · | -3.1% | -2.8% | -2.9% | · | 3.0% | 0.75% | -3.8% | · | -3.5% | -6.8% | -4.5% | · | -7.4% | |
| ROE | -3.6% | -4.8% | · | -5.3% | -5.5% | -5.8% | · | 6.6% | 2.1% | -10.4% | · | -9.9% | -22.3% | -45.2% | · | -30.8% |
Likuiditas & Solvabilitas 5
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.7 | · | 3.9 | 2.9 | 2.9 | · | 2.4 | 2.0 | 1.8 | · | 1.3 | 1.6 | 2.0 | · | 2.2 | |
| Quick Ratio | 1.7 | 1.9 | · | 2.3 | 1.9 | 1.9 | · | 1.5 | 1.5 | 1.2 | · | 0.8 | 0.8 | 1.1 | · | 1.1 | |
| Debt / Equity | 0.3 | 0.2 | · | 0.2 | 0.3 | 0.3 | · | 0.3 | 0.4 | 0.4 | · | 0.4 | 1.0 | 0.7 | · | 0.9 | |
| LT Debt / Equity | 0.2 | 0.2 | · | 0.2 | 0.3 | 0.3 | · | 0.3 | 0.4 | 0.4 | · | 0.2 | 0.5 | 0.5 | · | 0.6 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -3.1 | · | -4.2 | -7.5 | -3.7 | · | -7.8 |
Efisiensi 3
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.4 | · | 0.5 | 0.6 | 0.5 | · | 0.4 | 0.4 | 0.5 | · | 0.3 | |
| Inventory Turnover | 4.2 | 3.6 | · | 2.8 | 2.7 | 2.9 | · | 3.9 | 3.6 | 3.4 | · | 4.1 | 3.1 | 3.1 | · | 4.0 | |
| Receivables Turnover | 2.2 | 1.9 | · | 1.9 | 1.7 | 1.8 | · | 3.1 | 3.2 | 2.6 | · | 2.8 | 2.7 | 3.0 | · | 2.8 |
Valuasi (TTM) 14
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $67M | $68M | · | $79M | $89M | $96M | · | $101M | $90M | $84M | · | $80M | $75M | $73M | · | $69M | |
| Net Income TTM | $-6M | $-6M | · | $-3M | $-1M | $-1M | · | $-2M | $-7M | $-9M | · | $-11M | $-14M | $-18M | · | $-24M | |
| Market Cap | $22M | $35M | · | $47M | $29M | $39M | · | $128M | $55M | $49M | · | $59M | $92M | $23M | · | $15M | |
| Enterprise Value | $20M | $34M | · | $42M | $25M | $36M | · | $124M | $51M | $51M | · | $60M | $92M | $21M | · | $16M | |
| P/E | -30.6 | -4.9 | · | -12.0 | -21.2 | -22.6 | · | -49.6 | -5.9 | -4.0 | · | -3.6 | -5.8 | -1.1 | · | -0.6 | |
| P/S | 0.3 | 0.5 | · | 0.6 | 0.3 | 0.4 | · | 1.3 | 0.6 | 0.6 | · | 0.7 | 1.2 | 0.3 | · | 0.2 | |
| P/B | 0.6 | 1.0 | · | 1.3 | 1.0 | 1.2 | · | 4.4 | 2.3 | 2.4 | · | 2.8 | 9.6 | 1.8 | · | 0.9 | |
| P / Tangible Book | 0.9 | 1.4 | · | 1.8 | 1.5 | 1.9 | · | 7.2 | 4.5 | 5.4 | · | 6.1 | 10.7 | 2.0 | · | 1.0 | |
| P / Cash Flow | · | -210.4 | · | · | · | -11.1 | · | · | · | -20.6 | · | · | · | -5.9 | · | · | |
| P / FCF | · | -59.3 | · | · | · | -10.9 | · | · | · | · | · | · | · | · | · | · | |
| EV / EBITDA | -19.2 | -35.5 | · | -26.8 | -18.9 | -43.7 | · | 64.2 | 99.1 | -65.1 | · | -34.8 | -31.1 | -16.7 | · | -4.3 | |
| EV / FCF | · | -58.2 | · | · | · | -10.1 | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 0.3 | 0.5 | · | 0.5 | 0.3 | 0.4 | · | 1.2 | 0.6 | 0.6 | · | 0.8 | 1.2 | 0.3 | · | 0.2 | |
| Earnings Yield | -3.3% | -20.2% | · | -8.3% | -4.7% | -4.4% | · | -2.0% | -17.1% | -24.7% | · | -27.9% | -17.2% | -88.4% | · | -181.1% |
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
Laporan Laba Rugi
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Pendapatan | $69M | $101M | $84M | $73M | $62M |
| Margin Kotor % | 16.9% | 17.2% | 10.4% | 5.6% | -3.9% |
| Margin Operasi % | -6.8% | 0.60% | -8.0% | -23.1% | -49.0% |
| Laba Bersih | $-5M | $-480.0K | $-8M | $-19M | $-33M |
| EPS Dilusian | $-0.15 | $-0.03 | $-0.37 | $-1.31 | $-3.83 |
Neraca
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Utang / Ekuitas | 0.2 | 0.3 | 0.4 | 0.7 | 8.1 |
| Rasio Lancar | 4.0 | 2.6 | 1.7 | 2.0 | 1.7 |
| Rasio Cepat | 2.0 | 1.7 | 1.2 | 0.9 | 0.9 |
Arus Kas
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Arus Kas Bebas | $-1M | $3M | — | — | — |
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
📊
Pilih metrik yang penting bagi Anda — klik ➕ di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Pemilik institusional (13F) 36 pengaju · $2.7M total · Per tanggal 30 Juni 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 9 (-5 vs Kuartal sebelumnya) | 15 (+10 vs Kuartal sebelumnya) | 6 (-2 vs Kuartal sebelumnya) | 9 (0 vs Kuartal sebelumnya) | -379K |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| VANGUARD GROUP INC | $986.089 | 1.182.361 | 36,75% | Saham |
| VANGUARD CAPITAL MANAGEMENT LLC | $677.668 | 1.229.888 | 25,26% | Saham |
| RENAISSANCE TECHNOLOGIES LLC | $197.999 | 359.672 | 7,38% | Saham |
| GEODE CAPITAL MANAGEMENT, LLC | $169.240 | 288.030 | 6,31% | Saham |
| VANGUARD FIDUCIARY TRUST CO | $128.196 | 232.660 | 4,78% | Saham |
| Wealthspire Advisors, LLC | $83.587 | 151.838 | 3,12% | Saham |
| JANE STREET GROUP, LLC | $81.822 | 148.633 | 3,05% | Saham |
| BlackRock, Inc. | $79.688 | 144.756 | 2,97% | Saham |
| STATE STREET CORP | $55.548 | 100.904 | 2,07% | Saham |
| NORTHERN TRUST CORP | $50.570 | 91.862 | 1,88% | Saham |
| PANAGORA ASSET MANAGEMENT INC | $38.179 | 69.353 | 1,42% | Saham |
| CORSAIR CAPITAL MANAGEMENT, L.P. | $27.525 | 50.000 | 1,03% | Saham |
| LPL Financial LLC | $22.163 | 40.259 | 0,83% | Saham |
| WealthTrust Axiom LLC | $18.166 | 33.000 | 0,68% | Saham |
| Spartan Wealth Advisory Services LLC | $13.768 | 25.010 | 0,51% | Saham |
| TWO SIGMA SECURITIES, LLC | $13.621 | 24.743 | 0,51% | Saham |
| Tower Research Capital LLC (TRC) | $7.919 | 14.386 | 0,30% | Saham |
| Burford Brothers, Inc. | $7.799 | 14.168 | 0,29% | Saham |
| XTX Topco Ltd | $6.157 | 11.184 | 0,23% | Saham |
| Vanguard Global Advisers, LLC | $5.825 | 10.571 | 0,22% | Saham |
| Savvy Advisors, Inc. | $5.505 | 10.000 | 0,21% | Saham |
| WELLS FARGO & COMPANY/MN | $2.753 | 5.000 | 0,10% | Saham |
| MORGAN STANLEY | $1.091 | 1.982 | 0,04% | Saham |
| SHP Wealth Management | $782 | 1.421 | 0,03% | Saham |
| IFG Advisory, LLC | $369 | 670 | 0,01% | Saham |
| GROUP ONE TRADING LLC | $255 | 463 | 0,01% | Saham |
| JONES FINANCIAL COMPANIES LLLP | $168 | 258 | 0,01% | Saham |
| OSAIC HOLDINGS, INC. | $150 | 274 | 0,01% | Saham |
| COMERICA BANK | $136 | 163 | 0,01% | Saham |
| BARCLAYS PLC | $115 | 209 | 0,00% | Saham |
| UBS Group AG | $110 | 200 | 0,00% | Saham |
| FIFTH THIRD BANCORP | $90 | 163 | 0,00% | Saham |
| GSA CAPITAL PARTNERS LLP | $38 | 69.800 | 0,00% | Saham |
| Farther Finance Advisors, LLC | $21 | 39 | 0,00% | Saham |
| Richmond Brothers, Inc. | $3 | 6 | 0,00% | Saham |
| FMR LLC | $3 | 6 | 0,00% | Saham |
Orang dalam perusahaan 33 orang dalam · 17 pejabat · 18 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Mark Strobeck | President and CEO | 1 Juli 2026 A | 62.349 | 0 | 0 | $0 |
| Stuart M Paul | Chief Executive Officer | 4 Sep. 2019 F | 330.056 | 0 | 0 | $0 |
| CHIOINI ROBERT L | Chairman, President and CEO | 15 Des. 2017 M | 2.549.907 | 0 | 0 | $0 |
| Jesse Neri | SVP and CFO | 1 Juli 2026 A | 27.239 | 0 | 0 | $0 |
| Russell Skibsted | EVP, Chief Financial Officer and Chief Business Officer | 9 Sep. 2022 A | — | 0 | 0 | $0 |
| Angus W. Smith | Chief Financial Officer | 28 Nov. 2019 F | 168.486 | 0 | 0 | $0 |
| Thomas E Klema | Vice President, CFO | 15 Des. 2017 M | 671.492 | 0 | 0 | $0 |
| Heather Hunter | Chief Operating Officer | 1 Juli 2026 A | 28.007 | 0 | 1 | $-3.413 |
| Megan C. Timmins | EVP, CLO & Secretary | 1 Juli 2026 A | 31.240 | 0 | 0 | $0 |
| Timothy Chole | SVP, Chief Commercial Officer | 20 Mei 2025 A | 131.035 | 0 | 0 | $0 |
| Marc L Hoffman | Chief Medical Officer | 17 Maret 2023 A | 25.665 | 0 | 0 | $0 |
| Paul E Mcgarry | SVP, Finance and CAO | 17 Maret 2023 A | 28.515 | 0 | 0 | $0 |
| Ajay Gupta | Sr. VP & Chief Scientific Off. | 7 Okt. 2019 F | 576.458 | 0 | 0 | $0 |
| David Kull | Principal Accounting Officer | 25 April 2019 A | 13.270 | 0 | 0 | $0 |
| Raymond Dennis Pratt | Chief Medical Officer | 25 April 2019 A | 357.970 | 0 | 0 | $0 |
| Annamaria T Kausz | VP of Drug Development | 23 Sep. 2011 A | — | 0 | 0 | $0 |
| Richard C Yocum | VP - Clin. Dev. & Med. Affairs | 15 Jan. 2010 A | — | 0 | 0 | $0 |
| Joseph H Dawson | Direktur | 1 Juli 2026 A | 12.133 | 0 | 0 | $0 |
| Joan Lau | Direktur | 1 Juli 2026 A | 20.944 | 0 | 0 | $0 |
| Robert S Radie | Direktur | 1 Juli 2026 A | 23.985 | 0 | 0 | $0 |
| Allen Nissenson | Direktur | 1 Juli 2026 A | 23.892 | 0 | 0 | $0 |
| John G Cooper | Direktur | 1 Juli 2026 A | 23.670 | 0 | 0 | $0 |
| Andrea Heslin Smiley | Direktur | 20 Mei 2025 A | 142.062 | 0 | 0 | $0 |
| Mark H Ravich | Direktur | 20 Mei 2025 A | 148.831 | 0 | 0 | $0 |
| John Peter Mclaughlin | Direktur | 29 Jan. 2020 A | 35.174 | 0 | 0 | $0 |
| Russell H Ellison | Direktur | 9 Jan. 2020 A | 10.050 | 0 | 0 | $0 |
| Benjamin Wolin | Direktur | 6 Juni 2019 A | 27.710 | 0 | 0 | $0 |
| Robin L Smith | Direktur | 6 Juni 2019 A | 31.366 | 0 | 0 | $0 |
| Lisa N Colleran | Direktur | 6 Juni 2019 A | 18.674 | 0 | 0 | $0 |
| Patrick J Bagley | Direktur | 19 Maret 2018 A | 116.307 | 0 | 0 | $0 |
| Ronald D Boyd | Direktur | 19 Maret 2018 A | 42.678 | 0 | 0 | $0 |
| Kenneth L Holt | Direktur | 16 Maret 2017 S | 12.630 | 0 | 0 | $0 |
| HAGELSTEIN DAVID A | Pemilik 10% | 28 Jan. 2013 J | 1.360.700 | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Aktivis & pemilik 5%+ 15 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| Richmond Brothers, Inc., RBI Private Investment I, LLC, RBI Private Investment II, LLC, The RBI Opportunities Fund, LLC, The RBI Opportunities Fund II, LLC, RBI PI Manager, LLC, Richmond Brothers 401(k) Profit Sharing Plan, David S. Richmond, Matthew J. Curfman ×18 pengajuan | 6 Sep. 2023 | — | Pengajuan awal | — | SEC |
| Robert L. Chioini ×10 pengajuan | 29 Des. 2017 | — | Pengajuan awal | — | SEC |
| David Hagelstein Charitable Remainder Unitrust dated November 20, 2003, as amended, David A. Hagelstein | 13 Agu 2013 | — | Pengajuan awal | — | SEC |
| Thomas E. Klema ×3 pengajuan | 1 Juli 2013 | — | Pengajuan awal | — | SEC |
| Thomas E. Klema (2) | 23 Maret 2012 | — | Pengajuan awal | — | SEC |
| David Hagelstein Charitable Remainder Unitrust dated November 20, 2003, David A. Hagelstein | 8 Des. 2011 | — | Pengajuan awal | — | SEC |
| David Hagelstein Charitable Remainder Unitrust Agreement, dated November 20, 2003, David A. Hagelstein, individually and the David A. Hagelstein Revocable Living Trust, dated October 27, 1993 ×4 pengajuan | 31 Maret 2011 | — | Pengajuan awal | Investasi pasif | SEC |
| Orang pelapor yang tidak diungkapkan | 13 Feb. 2007 | — | Pengajuan awal | Investasi pasif | SEC |
| Orang pelapor yang tidak diungkapkan | 13 Feb. 2007 | — | Pengajuan awal | Investasi pasif | SEC |
| Orang pelapor yang tidak diungkapkan | 6 Feb. 2006 | — | Pengajuan awal | Investasi pasif | SEC |
| Orang pelapor yang tidak diungkapkan | 27 Des. 2005 | — | Pengajuan awal | Investasi pasif | SEC |
| Orang pelapor yang tidak diungkapkan | 27 Des. 2005 | — | Pengajuan awal | Investasi pasif | SEC |
| Orang pelapor yang tidak diungkapkan | 18 Juli 2005 | — | Pengajuan awal | Investasi pasif | SEC |
| Orang pelapor yang tidak diungkapkan | 22 April 2005 | — | Pengajuan awal | Investasi pasif | SEC |
| Orang pelapor yang tidak diungkapkan | 23 Jan. 2004 | — | Pengajuan awal | Investasi pasif | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Kepemilikan ETF Dimiliki oleh 2 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.